Abstract
The roles of the N-methyl-D-aspartate (NMDA) receptor and NMDA receptor-mediated synaptic plasticity are reviewed in the context of depressive disorder and its treatment. The mode of action of antidepressant treatment is poorly understood. Animal studies have suggested that many antidepressant drugs show activity at the NMDA receptor and that NMDA antagonists have antidepressant profiles in preclinical models of depression. A post-mortem study in humans has suggested that certain binding characteristics of the NMDA receptor may be down-regulated in the brains of suicide victims. "Depressogenic" stressors in animals and chronic administration of antidepressant agents perturb NMDA-dependent synaptic plasticity in the hippocampus. (C) 2000 Elsevier Science Inc. All rights reserved.
| Original language | English |
|---|---|
| Pages (from-to) | 11-25 |
| Number of pages | 15 |
| Journal | Pharmacology & Therapeutics |
| Volume | 87 |
| Issue number | 1 |
| Publication status | Published - Jul 2000 |
UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 3 Good Health and Well-being
Fingerprint
Dive into the research topics of 'The N-methyl-D-aspartate receptor, synaptic plasticity, and depressive disorder: a critical review'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver